10-K: Protalix BioTherapeutics Reports 2025 Results, Advances Pipeline

Protalix BioTherapeutics reported its financial results for the fiscal year ended December 31, 2025, highlighting a net loss and increased R&D expenses while advancing its rare disease pipeline and securing a new Elfabrio dosing approval in the EU.

Summary

• Protalix BioTherapeutics is a commercial stage biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases.
• The company utilizes its proprietary ProCellEx plant cell-based protein expression system.
• Two commercial products are Elelyso (for Gaucher disease) and Elfabrio (for Fabry disease).
• The pipeline includes PRX-115 for uncontrolled gout (currently in Phase 2, RELEASE study actively recruiting) and PRX-119 for NETs-related diseases (preclinical stage).
• A collaboration with Secarna Pharmaceuticals GmbH & Co. KG is ongoing for novel antisense oligonucleotide (ASO) therapies targeting rare renal indications.
• The company reported a net loss of $6.604 million for the year ended December 31, 2025, a decrease from a net income of $2.932 million in 2024.
• Total revenue slightly decreased to $52.744 million in 2025 from $53.399 million in 2024.
• Research and development expenses increased by 51% to $19.569 million in 2025, primarily due to preparations for the RELEASE study.
• Selling, general, and administrative expenses decreased by 4% to $11.682 million in 2025.
• Cash and cash equivalents and short-term bank deposits totaled $30.3 million as of December 31, 2025.
• The European Commission (EC) ratified a positive opinion on March 5, 2026, approving the 2 mg/kg E4W dosing regimen for Elfabrio in Fabry disease adult patients stable with ERT treatment in the EU.
• Fundação Oswaldo Cruz (Fiocruz) in Brazil has not complied with certain purchase commitments for BioManguinhos alfataliglicerase (Elelyso), and the company expects this non-compliance to continue.
• The company believes its current funds are sufficient to satisfy capital needs for at least 12 months from the report issuance date.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a challenging period due to the shift from net income to a significant net loss and decreased total revenue, despite positive clinical progress and a new EU approval for Elfabrio. The increased R&D spend is a necessary investment, but the financial performance indicates headwinds.

Positives

• The European Commission (EC) ratified a positive opinion on March 5, 2026, approving the 2 mg/kg E4W dosing regimen for Elfabrio in Fabry disease adult patients stable with ERT treatment in the EU, following a successful appeal.
• Elfabrio has been approved for marketing in more than 10 additional markets since its initial approvals in May 2023.
• The Phase 1 clinical trial for PRX-115 (for uncontrolled gout) demonstrated rapid reduction in plasma urate levels, dose-dependent effect and duration, and was generally well-tolerated with mostly mild to moderate transient adverse events.
• Results from the PRX-115 Phase 1 study suggest potential for a wide dosing interval, which could enhance patient compliance and treatment flexibility for gout patients.
• The Phase 2 RELEASE study for PRX-115 is actively recruiting patients, with the first patients already randomized.
• Preclinical data for PRX-119 (Long Acting DNase I) showed a decrease in circulating DNA levels and significantly enhanced survival in sepsis and ARDS animal models.
• The company is engaged in a collaborative research project with Secarna Pharmaceuticals GmbH & Co. KG to discover novel antisense oligonucleotide (ASO) therapies for rare renal indications.
• Protalix BioTherapeutics was added to the Russell 3000 and Russell 2000 Indexes, effective June 27, 2025, enhancing market visibility.
• The company's manufacturing facility in Carmiel, Israel, is an approved multi-product facility and has successfully passed inspections by various regulatory authorities, including the FDA and EMA.
• A regulatory milestone payment of $25.0 million from Chiesi was triggered by the EC's approval of the E4W dosing regimen for Elfabrio (subsequent event).

Negatives

• The company reported a net loss of $6.604 million for the year ended December 31, 2025, a significant decline from a net income of $2.932 million in 2024.
• Total revenue decreased by 1.2% to $52.744 million in 2025 compared to $53.399 million in 2024.
• Operating income turned into an operating loss of $5.500 million in 2025, compared to an operating income of $3.917 million in 2024.
• Net cash used in operating activities was $11.993 million in 2025, a substantial increase from $8.674 million provided by operating activities in 2024.
• Sales of Elfabrio to Chiesi decreased by $6.820 million in 2025, primarily due to changes in the average net selling price and quantities sold to Chiesi's inventory.
• Fiocruz has not complied with certain purchase commitments under the Brazil Agreement for BioManguinhos alfataliglicerase (Elelyso), and the company expects this non-compliance to continue.
• One subject in the PRX-115 Phase 1 study experienced an anaphylactic reaction, leading to the administration of premedication to all subsequent subjects.
• Approximately 50% of subjects in the PRX-115 Phase 1 study developed anti-drug antibodies (ADAs).
• The company has never declared or paid any cash dividends on its capital stock and does not anticipate doing so in the foreseeable future.
• The company has a limited commercial operating history, which may limit investors' ability to make informed decisions.
• The company is a holding company with no operations of its own, dependent on the earnings of its subsidiary, Protalix Ltd.
• The company's ability to utilize net operating loss (NOL) carryforwards may be limited under Section 382 of the Internal Revenue Code (IRC).
• The corporate structure may create U.S. federal income tax inefficiencies.

Risks

• Heavy dependence on revenues from sales of Elfabrio and Elelyso, with commercialization efforts largely controlled by partners (Chiesi, Pfizer, Fiocruz).
• Products or future product candidates may cause serious adverse events or undesirable side effects, potentially halting clinical development, delaying/preventing regulatory approval, or limiting commercial potential (e.g., Elfabrio's boxed warning for hypersensitivity reactions/anaphylaxis).
• Discovery of previously unknown safety issues post-approval could negatively affect commercial sales, lead to product restrictions, or market withdrawal.
• Physicians, patients, third-party payors, and others in the medical community may not accept and use current or future products.
• Market opportunities for rare diseases may be smaller than currently estimated, adversely affecting revenues.
• Coverage and reimbursement may not be available for products in all territories, diminishing sales or profitability.
• Exposure to federal and state healthcare fraud and abuse and false claims laws and regulations.
• Failure to supply drug substance to Chiesi or Pfizer could result in substantial financial penalties.
• Inability to enhance the portfolio of product candidates through internal research or strategic collaborations.
• Manufacturing problems or inability to maintain compliance with current Good Manufacturing Practices (cGMP) by the company or its providers.
• Reliance on third parties for final processing (fill and finish) exposes the company to risks of delays, higher costs, or inability to secure suitable partners.
• Developments by competitors may render products or technologies obsolete or non-competitive, including gene therapies for Fabry and Gaucher diseases, and other gout treatments.
• Failure to maintain an effective system of internal control over financial reporting could lead to inaccurate financial reporting or fraud.
• Internal computer systems or those of third-party contractors may fail or suffer security breaches, resulting in liability and harm to reputation.
• Product liability claims could result in reduced demand for products or damages exceeding insurance coverage.
• Ability to utilize net operating loss carryforwards may be limited by IRC Section 382.
• Corporate structure may create U.S. federal income tax inefficiencies.
• Outbreaks of contagious disease or similar public health threats could materially and adversely affect business operations and financial condition.
• Operating costs and business operations could be adversely affected by climate-related events and increasing regulatory requirements.
• Delays in obtaining necessary U.S., EMA, or other worldwide regulatory approvals for drug candidates.
• Preclinical and clinical trials are very expensive, time-consuming, and difficult to design and implement, with a high risk of failure.
• Clinical trial results may not support claims of safety or efficacy, or may identify serious side effects, delaying or forcing abandonment of development.
• Difficulty enrolling or retaining patients in clinical trials, especially for rare diseases.
• Regulatory approval in one jurisdiction does not guarantee approval in others, and failure in one may negatively impact others.
• Dependence on third-party service providers for clinical trials introduces risks beyond direct control.
• Limited experience in regulatory affairs compared to larger competitors, potentially leading to longer regulatory processes.
• Uncertainty surrounding and future changes to healthcare law in the United States and other government mandates.
• Failure to meet continued market capitalization-based listing requirements or other continued listing requirements of the NYSE American.
• Need to raise additional capital, which may not be available on favorable terms or at all, leading to dilutive effects on stockholders.
• Failure to adequately protect or enforce intellectual property rights or secure rights to third-party patents, diminishing the value of intellectual property.
• Reliance on confidentiality agreements that could be breached or difficult to enforce.
• Infringement of third-party intellectual property rights could lead to substantial costs, litigation, or inability to sell products.
• Inability to meet requirements under license agreements could result in loss of product rights.
• Significant parts of operations are located in Israel, exposing the company to military, political, and economic conditions in the region, including ongoing conflicts.
• Operations may be disrupted by the obligations of personnel to perform military service in Israel.
• Exposure to currency fluctuations and inflation, particularly with the New Israeli Shekel (NIS) and Euro.
• Tax benefits available in Israel require meeting several conditions and may be terminated or reduced in the future.
• Israeli government grants received for R&D expenditures restrict the ability to manufacture products and transfer technologies outside of Israel, with potential penalties for non-compliance.
• Investors may have difficulties enforcing U.S. judgments against the company or its non-U.S. resident executive officers and directors.

Future Outlook

The company intends to retain any future earnings to finance business growth and development, not anticipating cash dividends in the foreseeable future. It expects to continue incurring significant, increasing research and development expenses as the PRX-115 RELEASE study progresses and more advanced preclinical/clinical trials for other product candidates commence. Expenses are anticipated to increase as the company seeks to in-license additional technologies, continue preclinical/clinical trials, and seek regulatory approvals. While revenues from Elfabrio and Elelyso are expected to increase, they may not be sufficient to fund all expenditures, necessitating potential future financing through collaborations, equity offerings, or debt. The company believes current funds are sufficient for at least 12 months from the report issuance date, and anticipates continuing currency hedging transactions in 2026.

Management Comments

• "We are a commercial stage biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs."
• "ProCellEx, our unique, proprietary plant cell-based protein expression system represents a new method for developing recombinant proteins in an industrial-scale manner."
• "We currently intend to retain any future earnings to finance the growth and development of our business and therefore do not anticipate paying any cash dividends in the foreseeable future."
• "We are committed to leveraging our track record of success as we progress with the development of treatments for rare and orphan diseases."
• "We believe that our treatments of interest will address both genetic and non-genetic diseases."
• "We believe that the benefits of increased protection of our ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging takeover or acquisition proposals because, among other things, negotiation of these proposals could result in an improvement of their terms."
• "We believe that our cash and cash equivalents and short-term bank deposits as of December 31, 2025 are sufficient to satisfy our capital needs for at least 12 months from the date that these financial statements are issued."
• "Our management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles."
• "Based on our assessment, management has concluded that our internal control over financial reporting was effective as of the end of the fiscal year to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles."

Industry Context

StockSavvy.ai notes that Protalix operates in the highly competitive and rapidly evolving biotechnology and pharmaceutical industries, characterized by significant R&D, manufacturing, and marketing resources from larger established companies. The focus on rare and orphan diseases, while offering potential for premium pricing and orphan drug exclusivity, also presents challenges in patient recruitment for clinical trials and smaller market opportunities. The company's plant cell-based expression system (ProCellEx) is a differentiating factor in a market dominated by mammalian cell systems, offering potential advantages in production and safety. The ongoing regional conflict in Israel introduces geopolitical risk, a factor unique to companies with significant operations in the region, potentially impacting supply chains and business continuity.

Comparison to Industry Standards

• The global market for therapies for Gaucher disease was $1.65 billion in 2025, forecasted to be approximately $1.6 billion in 2026, and is expected to grow at a compound annual growth rate (CAGR) of approximately 0.5% from 2025-2031. Protalix's Elelyso competes with Sanofi Genzyme's Cerezyme, Takeda's Vpriv, and Sanofi's Cerdelga (an oral treatment).
• The global market for therapies for Fabry disease is forecasted to be approximately $2.3 billion in 2026 and is expected to grow at a CAGR of 6.3% from 2025-2031, reaching approximately $3.2 billion in annual sales in 2031. Protalix's Elfabrio competes with Takeda's Replagal, Sanofi Genzyme's Fabrazyme, and Amicus Therapeutics' Galafold. Additionally, Sangamo Therapeutics, Inc. is developing a gene therapy (ST-920) for Fabry disease, with a rolling Biologics License Application (BLA) submission initiated.
• For uncontrolled gout, Protalix's PRX-115 is in development and competes with Amgen Inc.'s Krystexxa. Swedish Orphan Biovitrum AB (Sobi) has developed Pegadriscase (NASP), which recently completed a Phase 3 clinical trial, and the FDA has set a Prescription Drug User Fee Act (PDUFA) target action date in June 2026 for its review.
• Protalix's ProCellEx system, a plant cell-based protein expression platform, competes with alternative expression technologies from companies such as Crucell N.V. (human-cell technology), Dyadic International Inc. (fungus-based), Pfenex Inc. (bacteria-based), and other plant-based technologies from iBio, Inc., Medicago, Inc., and Eleva Biologics.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not involved in any material legal proceedings.

Related Party Transactions

• Compensation (including share-based compensation) to non-executive directors totaled $478,000 for the year ended December 31, 2025.
• An engagement of one non-executive director to advise the company regarding business development and licensing efforts on a consultancy basis expired in September 2025. No consulting fees were recorded for this engagement in 2025, compared to $1,350 in 2024 and $35,475 in 2023.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings, continued market price volatility, and no anticipated cash dividends. Anti-takeover provisions in organizational documents could limit opportunities for a premium on common stock.
• Employees are subject to compensation including share-based awards and face potential disruptions to operations due to military service obligations in Israel.
• Customers (via partners) benefit from the continued supply of Elelyso and Elfabrio, including the new Elfabrio dosing regimen in the EU, and potential future treatments from the pipeline (PRX-115, PRX-119).
• Partners (Pfizer, Chiesi, Fiocruz) continue their collaboration, with Chiesi responsible for global commercialization of Elfabrio and Pfizer for Elelyso (ex-Brazil). Fiocruz's non-compliance with purchase commitments for Elelyso in Brazil remains an ongoing issue.
• Creditors saw the repayment in full of the 2024 Notes in September 2024, but the company anticipates potential future debt financings.

Next Steps

• Actively recruiting for and randomizing first patients in the Phase 2 RELEASE study of PRX-115 for uncontrolled gout.
• Chiesi is sponsoring a pediatric clinical trial (FLY Study, NCT06328608) for Elfabrio, with recruitment ongoing.
• Chiesi is recruiting patients for the Japanese RISE study (NCT05710692) to evaluate Elfabrio's safety and efficacy in Japanese patients.
• Continue to identify alternative approved suppliers for raw materials to ensure uninterrupted supply.
• Prepare to expand manufacturing space within the current facility to add additional purification capabilities in anticipation of future needs for potential commercialization of PRX-115.
• Continuously evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies and academic research institutions.
• Explore novel platform technologies to expand the pipeline.
• Anticipate applying for restorations of the patent term for certain patents covering product candidates.
• Expects to contribute approximately $1,180,000 in the year ending December 31, 2026, to insurance companies in connection with severance liabilities.

Key Dates

Recommendation

The company faces significant financial challenges, including a net loss and decreased revenue in 2025, alongside increased R&D expenses. However, the positive clinical trial data for PRX-115 and the recent EU approval for an expanded Elfabrio dosing regimen provide a basis for future growth. The company's cash position is deemed sufficient for the next 12 months, but future capital raises are anticipated, which could lead to dilution. Given the mixed financial performance and the long-term potential of its pipeline, a "hold" recommendation is appropriate for investors to monitor the commercialization trajectory of Elfabrio and the progress of PRX-115.

Keywords

Biopharmaceutical, Rare diseases, Fabry disease, Gaucher disease, Uncontrolled gout, Elfabrio, Elelyso, PRX-115, ProCellEx, Clinical trials, SEC 10-K, Financial results, Biotechnology, Drug development, Corporate governance, Israel operations, NYSE American, Enzyme replacement therapy